Evaluating Cell-Free DNA Quantification and Integrity in Breast Cancer Using Fluorometric, Electrophoretic and PCR-Based Platforms
Authors:
- Gisha Rose AntonyGAGisha Rose Antony
- Vidya P. NimbalkarVNVidya P. Nimbalkar
- Sowmya NagarajSNSowmya Nagaraj
- Mahalakshmi SubramanyaMSMahalakshmi Subramanya
- Anupama C. Eshwara RaoARAnupama C. Eshwara Rao
- Ganapathi BantwalGBGanapathi Bantwal
- Belinda GeorgeBGBelinda George
- Akshay AjoyAAAkshay Ajoy
- Nihal M. AhamedNANihal M. Ahamed
- Rakesh S. RameshRRRakesh S. Ramesh
- Jyothi D. NJNJyothi D. N
- Jaya Kumari SJSJaya Kumari S
Open Access
- 24 August 2026
- journal article
- research article
- Published by MDPI AG in Methods and Protocols
- Vol. 9 (5) , 124
Abstract
Cell-free DNA (cfDNA) has emerged as a promising liquid biopsy biomarker; however, differences in analytical methods may influence cfDNA quantification and integrity assessment. This study compared plasma cfDNA concentration and integrity between treatment-naïve breast cancer (BC) patients (n = 100) and healthy controls (HC; n = 70) using complementary analytical platforms. cfDNA concentration was measured by Qubit fluorometry, TapeStation (TS) electrophoretic profiling, and ALU-based quantitative PCR (qPCR). An exploratory genomic DNA (gDNA) correction of Qubit-derived cfDNA concentration was performed using TS-derived fragment-size information. cfDNA integrity was assessed using the ALU-derived DNA Integrity Index (DII (ALU); ALU247/ALU115) and the TS-derived DNA Integrity Index (DII (TS)), and methods were compared for their correlation and agreement. Qubit- and TS-based cfDNA measurements were significantly higher in BC patients than in HC. Among the ALU-based qPCR measures, although ALU115 did not differ significantly between groups, ALU247 and DII (ALU) were significantly higher in BC patients, indicating an enrichment of longer cfDNA fragments. Exploratory gDNA correction did not substantially alter the observed differences. Significant positive correlations were observed among the cfDNA quantification methods. Supporting these findings, agreement analysis demonstrated improved agreement following gDNA correction. In contrast, cfDNA integrity assessment was method-dependent: although DII (ALU) was significantly higher in BC patients, DII (TS) did not differ significantly between groups, and no significant correlation or agreement was observed between the two indices, indicating that the two methods evaluate different lengths of cfDNA fragments. These findings demonstrate that complementary analytical platforms consistently differentiated BC patients from HC based on cfDNA concentration, whereas cfDNA integrity assessment depended on the analytical method employed. Together, these findings provide methodological insights into cfDNA quantification and fragmentation assessment and support the complementary use of fluorometric, electrophoretic, and ALU-based qPCR approaches for comprehensive cfDNA characterization.Keywords
All Related Versions
Funding Information
- Indian Council of Medical Research (IIRP-2023-1560)
This publication has 25 references indexed in Scilit:
- Liquid biopsies across the cancer care continuumNature Medicine, 2025
- Cell-free DNA fragmentomics in cancerCancer Cell, 2025
- Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patientsScientific Reports, 2023
- Alu cell-free DNA concentration, Alu index, and LINE-1 hypomethylation as a cancer predictorClinical Biochemistry, 2021
- Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burdenNature Communications, 2021
- Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCRScientific Reports, 2020
- Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast CancerApplied Biochemistry and Biotechnology, 2018
- Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patientsEuropean Journal of Cancer, 2018
- Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequenceJournal of the Egyptian National Cancer Institute, 2016
- Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosisBreast Cancer Research and Treatment, 2014